바이오테크 보도자료
-
- Boehringer Ingelheim and Click Therapeutics expand their existing Collaboration to develop Prescription Digital Therapeutics for Schizophrenia
- Boehringer Ingelheim and Click Therapeutics today announced the launch of an expanded collaboration for the development and commercialization of a second prescription-based digital therapeutic (PDT). The companies will collaborate to develop and c...
- 2022년 12월 20일
-
- Biocytogen Announces FDA Clearance of IND Application for Bispecific Antibody YH008
- Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) today announced that the US FDA has approved the Investigational New Drug (IND) application for a phase I study of YH008, an internally developed first-in-class PD-1 x CD40...
- 2022년 12월 19일
-
- CAS Introducing Transformational Capabilities to Accelerate Life Sciences Innovation
- CAS, a division of the American Chemical Society specializing in scientific information solutions, announced several initiatives to once again transform scientific research, and empower more rapid discovery for life sciences innovation. CAS is exp...
- 2022년 12월 16일
-
- Artilysin®: Fearless Into the Post-antibiotic Era
- The WHO has declared antibiotic resistances one of the Top 10 global threats to mankind. To counter this threat, Lysando AG has developed the so-called Artilysin® technology: Novel antimicrobial proteins with a unique mode of action. The Artilysin...
- 2022년 12월 16일
-
- Takeda to Acquire Late-Stage, Potential Best-in-Class, Oral Allosteric TYK2 Inhibitor NDI-034858 From Nimbus Therapeutics
- Takeda (TSE:4502/NYSE:TAK) today announced that it will acquire NDI-034858 from Nimbus Therapeutics. NDI-034858 is an oral, selective allosteric tyrosine kinase 2 (TYK2) inhibitor being evaluated for the treatment of multiple autoimmune diseases f...
- 2022년 12월 14일
-
- Cancellation of remaining publicly held registered shares of Vifor Pharma AG
- Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Vifor Pharma AG (“Vifor”) announced today that the Commercial Court St. Gallen has cancelled (kraftlos erklärt) all remaining publicly held registered shares of Vifor with a nominal value...
- 2022년 12월 14일
-
- JT Group Recognized on CDP’s “Climate Change A List” for the 4th Consecutive Year
- Japan Tobacco Inc. (JT) (TSE: 2914) has once again been recognized for its leadership in corporate sustainability by the global environmental non-profit organization CDP. JT achieved a place on CDP's prestigious “A List”[1] for tackling climate ch...
- 2022년 12월 14일
-
- AOP Health presents latest updates on BESREMi® (Ropeginterferon alfa-2b) in Polycythaemia Vera at the American Society of Hematology (ASH) 2022 Annual Meeting
- AOP Health announced its latest updates on Ropeginterferon alfa-2b in patients with Polycythaemia Vera (PV) from AOP Health´s CONTINUATION-PV study (Reference Kiladjian et al. ASH 2022) and the LOW-PV trial, which is an independent investigator-in...
- 2022년 12월 14일
-
- MRM Health and IFF Reach Second Milestone in the Partnered Type 2 Diabetes Program
- MRM Health—a clinical-stage biopharmaceutical company focused on developing next-generation live microbiome consortia therapeutics—today announced that its Type-2 Diabetes Program, developed in collaboration with IFF (NYSE: IFF) has achieved precl...
- 2022년 12월 13일
-
- Organon Appoints Kirke Weaver as General Counsel and Corporate Secretary
- Organon (NYSE: OGN), a global women’s healthcare company, today announced that Kirke Weaver has been appointed General Counsel and Corporate Secretary, and will continue as a member of Organon’s executive leadership team, effective January 1, 2023...
- 2022년 12월 13일
전시회
